Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling

Infectious Disease Clinics of North America

Volumn 32, Issue 2, 2018, Pages 461-480

  Chhatwal, Jagpreet ^a   Chen, Qiushi ^b   Aggarwal, Rakesh ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b The Pennsylvania State University   (United States)

^c SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cost effectiveness; Direct acting antivirals; Health economics; Hepatitis C elimination; Markov modeling; Public health; Simulation

Indexed keywords

ATTITUDE TO ILLNESS; BUDGET; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEPATITIS C; HISTORY; INCIDENCE; INFECTION CONTROL; MASS SCREENING; MATHEMATICAL MODEL; PREVALENCE; REVIEW; SIMULATION; UNITED STATES; VIRUS LOAD; COST OF ILLNESS; DRUG EFFECT; ECONOMIC MODEL; ECONOMICS; EPIDEMIC; GENOTYPE; HEPACIVIRUS; HUMAN; LEGISLATION AND JURISPRUDENCE; MARKOV CHAIN; PROCEDURES; PUBLIC HEALTH; THEORETICAL MODEL; VIROLOGY;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; COST OF ILLNESS; EPIDEMICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MODELS, THEORETICAL; PREVALENCE; PUBLIC HEALTH; UNITED STATES;

EID: 85047112961     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2018.02.008     Document Type: Review

References (58)

1. Blach, S., Zeuzem, S., Manns, M., et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2:3 (2017), 161–176.
2. Campbell, C.A., Canary, L., Smith, N., et al. State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs—United States, 2015-2016. MMWR Morb Mortal Wkly Rep 66:18 (2017), 465–469.
3. Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:16 (2014), 1483–1493.
4. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. 2016. Available from: http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. Accessed January 3, 2017.
5. National Academies of Sciences, Engineering, and Medicine. A national strategy for the elimination of hepatitis B and C. 2017, The National Academies Press, Washington, DC.
6. Denniston, M.M., Jiles, R.B., Drobeniuc, J., et al. Chronic Hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 160:5 (2014), 293–300.
7. He, T., Lopez-Olivo, M.A., Hur, C., et al. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther 2017:00 (2017), 1–11.
8. Aggarwal, R., Chen, Q., Goel, A., et al. Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. PLoS One, 12(5), 2017, e0176503.
9. Roberts, M.S., Smith, K.J., Chhatwal, J., Mathematical modeling. Gatsonis, C., Morton, S.C., (eds.) Methods in comparative effectiveness research, 2017, CRC Press, Boca Raton (FL), 409–446.
10. Chhatwal, J., Wang, X., Ayer, T., et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology 64:5 (2016), 1442–1450.
11. Kabiri, M., Chhatwal, J., Donohue, J.M., et al. Long-term disease and economic outcomes of prior authorization criteria for hepatitis C treatment in Pennsylvania Medicaid. Healthc (Amst) 5:3 (2017), 105–111.
12. Razavi, H., Elkhoury, A.C., Elbasha, E., et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 57:6 (2013), 2164–2170.
13. Rein, D.B., Smith, B.D., Wittenborn, J.S., et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 156:4 (2012), 263–270.
14. Liu, S., Cipriano, L.E., Holodniy, M., et al. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C Infection in the United States. PLoS One, 8(3), 2013, e58975.
15. Martin, N.K., Hickman, M., Miners, A., et al. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open, 3(8), 2013 [pii: e003153].
16. He, T., Li, K., Roberts, M.S., et al. Prevention of hepatitis C by screening and treatment in U.S. prisons. Ann Intern Med 164:2 (2016), 84–92.
17. Stone, J., Martin, N.K., Hickman, M., et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction 112:7 (2017), 1302–1314.
18. Assoumou, S.A., Tasillo, A., Leff, J.A., et al. Cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings. Clin Infect Dis 66:3 (2018), 376–384.
19. Canary, L.A., Klevens, R.M., Holmberg, S.D., Limited access to new hepatitis C virus treatment under state Medicaid programs. Ann Intern Med 163:3 (2015), 226–228.
20. Chhatwal, J., He, T., Hur, C., et al. Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving. Clin Gastroenterol Hepatol 15:6 (2017), 827–837.e8.
21. Chhatwal, J., Kanwal, F., Roberts, M.S., et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 162:6 (2015), 397–406.
22. Keeling, M.J., Rohani, P., Modeling infectious diseases in humans and animals. 2008, Princeton University Press, Princeton (NJ).
23. Kim, S.-Y., Goldie, S.J., Cost-effectiveness analyses of vaccination programmes. Pharmacoeconomics 26:3 (2008), 191–215.
24. Chhatwal, J., He, T., Economic evaluations with agent-based modelling: an introduction. Pharmacoeconomics 33:5 (2015), 423–433.
25. Koopman, J., Controlling smallpox. Science 298:5597 (2002), 1342–1344.
26. Rahmandad, H., Sterman, J., Heterogeneity and network structure in the dynamics of diffusion: comparing agent-based and differential equation models. Manage Sci 54:5 (2008), 998–1014.
27. Kabiri, M., Jazwinski, A.B., Roberts, M.S., et al. The changing burden of hepatitis C in the United States: model-based predictions. Ann Intern Med 161:3 (2014), 170–180.
28. Armstrong, G., Wasley, A., Simard, E., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med, 144(10), 2006, 705.
29. Surveillance for Viral Hepatitis—United States, 2013. 2016. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/HEPATITIS/Statistics/index.htm.
30. van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308:24 (2012), 2584–2593.
31. Stepanova, M., Kanwal, F., El-Serag, H.B., et al. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 53:3 (2011), 737–745.
32. Denniston, M.M., Klevens, R.M., McQuillan, G.M., et al. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology 55:6 (2012), 1652–1661.
33. Donohue, J.M., The impact and evolution of Medicare Part D. N Engl J Med 371:8 (2014), 693–695.
34. Congressional Budget Office. Updated budget projections: 2014 to 2024. Pub. No. 4928. 2014. Available at: http://www.cbo.gov/publication/45229. Accessed September 28, 2015.
35. Long, S.K., Kenney, G.M., Zuckerman, S., et al. Taking stock at mid-year: health insurance coverage under the ACA as of June 2014. 2014, Urban Institute Health Policy Center Available at: http://hrms.urban.org/briefs/taking-stock-at-mid-year.html. Accessed March 15, 2018.
36. Thein, H., Yi, Q., Dore, G., et al. Estimation of stage specific fibrosis progression rates in chronic hepatitis C virus infection: a meta analysis and meta regression. Hepatology (Baltimore, Md) 48:2 (2008), 418–431.
37. Fattovich, G., Giustina, G., Degos, F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112:2 (1997), 463–472.
38. Planas, R., Ballesté B., Antonio Álvarez, M., et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 40:5 (2004), 823–830.
39. Wolfe, R., Roys, E., Merion, R., Trends in organ donation and transplantation in the United States, 1999–2008. Am J Transplant 10:4p2 (2010), 961–972.
40. Arias, E., Heron, M., Xu, J.Q., United States life tables, 2013. National vital statistics reports; vol 66 no 3. 2017, National Center for Health Statistics, Hyattsville (MD).
41. Martin, N.K., Vickerman, P., Brew, I.F., et al. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology (Baltimore, Md) 63:6 (2016), 1796–1808.
42. Chhatwal, J., Chen, Q., Ayer, T., et al. Hepatitis C virus re-treatment in the era of direct–acting antivirals: projections in the USA. Aliment Pharmacol Ther 47 (2018), 1023–1031.
43. Chhatwal, J., Ferrante, S.A., Brass, C., et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health 16:6 (2013), 973–986.
44. McAdam-Marx, C., McGarry, L.J., Hane, C.A., et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 17:7 (2011), 531–546.
45. Eddy, D.M., Hollingworth, W., Caro, J.J., et al. Report of the ISPOR-SMDM modeling good research practices task force–7. Med Decis Making 32:5 (2012), 733–743.
46. Lang, K., Danchenko, N., Gondek, K., et al. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 50:1 (2009), 89–99.
47. El-Serag, H.B., Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127:5 (2004), S27–S34.
48. Blatt, L.M., Mutchnick, M.G., Tong, M.J., et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 7:3 (2000), 196–202.
49. Davis, G., Alter, M., El-Serag, H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138:2 (2010), 513–521.
50. Zeuzem, S., Andreone, P., Pol, S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 364:25 (2011), 2417–2428.
51. Poynard, T., Colombo, M., Bruix, J., et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 136:5 (2009), 1618–1628.
52. Cardoso, A.C., Moucari, R., Figueiredo-Mendes, C., et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 52:5 (2010), 652–657.
53. Thuluvath, P., Guidinger, M., Fung, J., et al. Liver transplantation in the United States, 1999–2008. Am J Transplant 10:4p2 (2010), 1003–1019.
54. Saab, S., Hunt, D.R., Stone, M.A., et al. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transplant 16:6 (2010), 748–759.
55. Surveillance for viral hepatitis—United States. Section: estimated actual new cases of HCV. 2013. Available at: http://www.cdc.gov/hepatitis/hcv/statisticshcv.htm - section1. Accessed February 2, 2016.
56. Volk, M.L., Tocco, R., Saini, S., et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (Baltimore, Md) 50:6 (2009), 1750–1755.
57. Silverman E. What the ‘shocking’ Gilead discounts on its hepatitis C drugs will mean. Wall Street Journal. 2015. Available at: http://blogs.wsj.com/pharmalot/2015/02/04/what-the-shocking-gilead-discounts-on-its-hepatitis-c-drugs-will-mean/. Accessed April 9, 2015.
58. Gilead sciences earnings report: Q2 2015 conference call transcript. 2015. Available at: https://seekingalpha.com/article/3366825-gilead-sciences-gild-ceo-john-martin-on-q2-2015-results-earnings-call-transcript. Accessed: September 28, 2015.